

5.40.009

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Cardiovascular Agents	Original Policy Date:	November 6, 2015
Subject:	Keveyis	Page:	1 of 5

Last Review Date: June 11, 2026

Keveyis

Description

Keveyis (dichlorphenamide)

Background

Keveyis (dichlorphenamide) is an oral carbonic anhydrase inhibitor indicated for the treatment of periodic paralysis. Periodic paralyses are a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis. Types of periodic paralyses are differentiated by criteria including underlying genetic mutations and changes in blood-potassium during attack. Hypokalemic and hyperkalemic are two common types of periodic paralyses (1).

Regulatory Status

FDA-approved indications: Keveyis is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants (2).

Keveyis includes a contraindication for hepatic insufficiency. Keveyis may aggravate hepatic encephalopathy. Keveyis also includes a contraindication for severe pulmonary disease. Keveyis can cause hyperchloremic non-anion gap metabolic acidosis. Patients with severe pulmonary disease may be unable to compensate for the metabolic acidosis caused by Keveyis. Concomitant use of Keveyis with other drugs that cause metabolic acidosis may increase the severity of metabolic acidosis. Baseline and periodic measurement of serum bicarbonate during Keveyis treatment are recommended. If metabolic acidosis develops or persists, consider reducing the dose or discontinuing Keveyis (2).

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Cardiovascular Agents	Original Policy Date:	November 6, 2015
Subject:	Keveyis	Page:	2 of 5

The use of Keveyis is contraindicated with concomitant use of high-dose aspirin. Anorexia, tachypnea, lethargy, and coma have been reported with co-administration of high-dose aspirin and Keveyis. Keveyis should be used with caution in patients receiving low-dose aspirin (2).

Keveyis increases potassium excretion and can cause hypokalemia. Baseline and periodic measurement of serum potassium are recommended. If hypokalemia develops or persists, consider reducing the dose or discontinuing Keveyis (2).

The safety and efficacy of Keveyis in pediatric patients 18 years or less have not been established (2).

Related policies

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Keveyis may be considered **medically necessary** if the conditions indicated below are met.

Keveyis may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Primary hyperkalemic periodic paralysis and related variants
2. Primary hypokalemic periodic paralysis and related variants

AND ALL of the following:

1. Baseline and periodic monitoring of serum potassium and bicarbonate levels
2. Diagnosis confirmed by **ONE** of the following:
 - a. Genetic testing
 - b. Provocative testing
 - c. Electromyography

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Cardiovascular Agents	Original Policy Date:	November 6, 2015
Subject:	Keveyis	Page:	3 of 5

- d. Muscle biopsy
- 3. Documentation that lifestyle modifications, dietary restrictions and exercise restrictions have been maximally challenged
- 4. Inadequate treatment response, intolerance, or contraindication to acetazolamide

AND NONE of the following:

- 1. Signs of hepatic impairment
- 2. Severe pulmonary disease
- 3. Use of high-dose aspirin

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

- 1. Primary hyperkalemic periodic paralysis and related variants
- 2. Primary hypokalemic periodic paralysis and related variants

AND the following:

- 1. Documentation that the patient has had a reduction in the number of paralytic attacks

AND NONE of the following:

- 1. Signs of hepatic impairment
- 2. Severe pulmonary disease
- 3. Use of high-dose aspirin

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity 360 tablets per 90 days

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Cardiovascular Agents	Original Policy Date:	November 6, 2015
Subject:	Keveyis	Page:	4 of 5

Duration 3 months

Prior – Approval *Renewal* Limits

Quantity 360 tablets per 90 days

Duration 12 months

Rationale

Summary

Keveyis (dichlorphenamide) is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. Keveyis has an unknown mechanism of therapeutic effect on patients with periodic paralysis. Keveyis can cause metabolic acidosis and use is contraindicated in patients with severe pulmonary disease. Keveyis may aggravate hepatic encephalopathy and use is contraindicated in patients with hepatic impairment. Co-administration of Keveyis with high-dose aspirin is contraindicated due to the risk of coma. Monitoring of potassium and bicarbonate levels is required at baseline and periodically throughout treatment with Keveyis. The safety and efficacy of Keveyis in pediatric patients 18 years or less have not been established (1-2).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Keveyis while maintaining optimal therapeutic outcomes.

References

1. National Institute of Neurological Disorders and Stroke. NINDS Familial Periodic Paralysis Information Page. <https://www.ninds.nih.gov/Disorders/All-Disorders/Familial-Periodic-Paralysis-Information-Page>. Published May 24, 2017.
2. Keveyis [package insert]. Chicago, IL. Xeris Pharmaceuticals, Inc.; July 2025.

Policy History

Date	Action
November 2015	Addition to PA
December 2015	Annual editorial review Addition of lifestyle, dietary and exercise requirements and trial of acetazolamide per PMPC

5.40.009

Section:	Prescription Drugs	Effective Date:	July 1, 2026
Subsection:	Cardiovascular Agents	Original Policy Date:	November 6, 2015
Subject:	Keveyis	Page:	5 of 5

December 2016	Annual editorial review Addition of age to renewal requirements Policy number change from 5.16.09 to 5.40.09
September 2017	Annual review and reference update
September 2018	Annual review and reference update
September 2019	Annual review
September 2020	Annual review and reference update
June 2021	Annual review
June 2022	Annual review
June 2023	Annual review. Changed policy number to 5.40.009
June 2024	Annual review and reference update
June 2025	Annual review and reference update
June 2026	Annual review and reference update

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 11, 2026 and is effective on July 1, 2026.